An atlas of genetic regulation and disease associations of 1

microRNAs 2

3

4 Rima Mustafa, MD MSc^{1,2}, Michelle M.J. Mens, PhD^{3,4}, Arno van Hilten, MSc⁵, Jian Huang,

5 PhD^{1,6}, Gennady Roshchupkin, PhD^{3,5}, Tianxiao Huan, PhD⁷, Linda Broer, PhD⁸, Paul Elliott,

MD PhD^{1,2,9,10,11}, Daniel Levy, MD^{12,13}, M. Arfan Ikram, MD PhD³, Marina Evangelou, PhD¹⁴, 6

7 Abbas Dehghan, MD PhD^{1,2,9*}, Mohsen Ghanbari, MD PhD^{2*}

- 8
- 9 Affiliations
- 10 ¹Department of Epidemiology and Biostatistics, Imperial College London, London, UK.
- 11 ²Dementia Research Institute, Imperial College London, London, UK.
- 12 ³Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.
- 13 ⁴Department of Epidemiology, Harvard T.H Chan School of Public Health, Boston, USA.
- 14 ⁵Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
- 15 ⁶Singapore Institute for Clinical Sciences (SICS), the Agency for Science, Technology and
- 16 Research (A*STAR), Singapore.
- ⁷Department of Ophthalmology and Visual Sciences, University of Massachusetts Medical 17
- 18 School, Worcester, MA, USA.
- 19 ⁸Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
- 20 ⁹MRC Centre for Environment and Health, Imperial College London, London, UK.
- 21 ¹⁰Health Data Research (HDR) UK. Imperial College London, London, UK.
- 22 ¹¹BHF Centre for Research Excellence, Imperial College London, London, UK.
- 23 ¹²Framingham Heart Study, Framingham, MA, USA.
- 24 ¹³Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of
- 25 Health, Bethesda, MD, USA.
- 26 ¹⁴Department of Mathematics, Imperial College London, London, UK.
- 27
- 28 *Abbas Dehghan and Mohsen Ghanbari are joint senior authors
- 29
- 30

31 Corresponding authors

- 32 Mohsen Ghanbari, MD PhD
- 33 Department of Epidemiology
- 34 Erasmus MC University Medical Center
- 35 Wytemaweg 80, 3015 CN
- 36 Rotterdam, The Netherlands
- 37 Email: <u>m.ghanbari@erasmusmc.nl</u>

38 Competing interests

- 39 None.
- 40
- 41
- 42
- 43

44 Abstract

45 MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression. Identification of genetic variants influencing the transcription of miRNAs can 46 47 provide an understanding of their genetic regulation and implication in human disease. Here 48 we present genome-wide association studies of 2,083 plasma circulating miRNAs measured 49 by next-generation sequencing in 2,178 participants of the Rotterdam Study to identify miRNA-50 expression quantitative trait loci (miR-eQTLs). We report 4,310 cis- and trans-miR-eQTLs for 51 64 miRNAs that have been replicated across independent studies. Many of these miR-eQTLs 52 overlap with gene expression, protein, and metabolite-QTLs and with disease-associated variants. The consequences of perturbation in miRNA transcription on a wide range of clinical 53 54 conditions are systematically investigated in phenome-wide association studies, with their 55 causality tested using Mendelian randomization. Integration of genomics and miRNAs enables interrogation of the genetic architecture of miRNAs, revealing their clinical importance, and 56 57 providing valuable resources for future studies of miRNAs in human disease.

58

59 Introduction

60 MicroRNAs (miRNAs) are small non-coding RNAs of approximately 22 nucleotides that regulate gene expression at the post-transcriptional level and play critical roles in determining 61 62 whether genes are (in)active and how much a particular protein is translated (1,2). Over 2,500 miRNAs have been identified in humans (3), which altogether regulate more than half of 63 64 protein-coding genes through cleavage or translation repression of messenger(m)-RNAs 65 (4,5). miRNAs have shown their potential as disease biomarkers (6) and, to a lesser extent, therapeutic targets (7). Identification of the role of miRNAs in regulating the expression of 66 67 specific genes and their effects in clinical conditions has been a subject of extensive work in 68 recent years. However, the genetic regulation of miRNAs remains less well understood.

69 Circulatory miRNAs are released from cells into circulation via extracellular vesicles such as 70 exosomes (8). Genetic variants are known to regulate the level of miRNAs in the circulation 71 (9-11) or tissues and cells (12-14), referred to as miRNA expression quantitative trait loci (miR-72 eQTLs). Previous studies showed that each miR-eQTL contributed to a relatively small 73 proportion of variation in miRNA levels (9,10), with a tiny proportion of miR-eQTLs replicated 74 across studies thus far (9). The identified miR-eQTLs have been used to study the effect of 75 perturbation of miRNA levels on disease risk (9,10,14). However, such an effect on a wide 76 range of clinical conditions remains to be elucidated. Unravelling the genetic regulation of 77 nearly all high confidence miRNAs can provide insights into their roles in affecting disease risk 78 and discover candidates for therapeutic targets.

79 This study measured plasma levels of 2,083 circulatory miRNAs in the population-based 80 Rotterdam Study cohort using a next-generation sequencing platform (HTG EdgeSeg miRNA 81 Whole Transcriptome Assay). This assay allows simultaneous, guantitative detection of 82 miRNAs with a sensitivity and specificity of 97% (15,16). Subsequently, genome-wide 83 association studies (GWAS) were conducted for 2,083 miRNAs to identify miR-eQTLs 84 (N=2,178), followed by replication in two independent cohorts (9,10). We conducted 85 downstream analyses to elucidate functional characteristics of the findings through cis and 86 trans mapping of miR-eQTLs, cross-phenotype, and multi-omics QTLs look-up. A systematic 87 investigation of the effects of genetically determined miRNA levels on a wide range of clinical 88 conditions was conducted using phenome-wide association studies (PheWAS) in the UK 89 Biobank (N=423,419) (17,18). We performed Mendelian randomisation (MR) to assess 90 causality between miRNAs and clinical conditions (19). Potential downstream target genes 91 that might be involved in the disease processes were highlighted, generating testable 92 hypotheses for further functional studies to dissect the underlying molecular pathways.

93 Results

Genome-wide identification and replication of miR-eQTLs 94

95 An overview of the study workflow is presented in Fig. 1. The list of 2,083 miRNAs characterised in this study is shown in Supplementary Table 1. The miRNA expression 96 97 profiling was performed for 2,754 participants from three sub-cohorts (RS-I-4, RS-II-2, and 98 RS-IV-1) in the Rotterdam Study (20). Genotype data were available for 2,435 of 2,754 99 participants. Participants of non-European ancestries and relatives based on kinship 100 coefficient > 0.088 were excluded, resulting in 2,178 participants in the analysis (Extended 101 Data Fig. 1). The clinical characteristics of participants are summarised in Supplementary 102 Table 2.

103 We identified 3,292 associations between 1,289 SNPs and 63 miRNAs at P<2.4×10⁻¹¹ 104 (genome-wide threshold of $P<5\times10^{-08}$ and Bonferroni-corrected for 2,083 miRNAs) 105 (Supplementary Table 3, Extended Data Fig. 2). After pruning with a series of linkage disequilibrium (LD) thresholds, the number of associations reduced to 75 (r^2 <0.1), 142 (r^2 <0.3), 106 107 and 297 (r²<0.6). The 3,292 identified associations included 1,733 cis associations for 32 108 miRNAs and 1,559 trans associations for 33 miRNAs. The overall proportion of variance 109 explained by each miR-eQTL ranged from 2% to 11% (median=2.9%). Eighteen miR-eQTLs 110 (r²<0.6) were explaining more than 5% of the variation of corresponding miRNA levels 111 (Supplementary Table 4). The highest proportion of variance explained was observed for miR-112 625-5p (11%) by rs2127868 (P=1.63x10⁻⁶⁰), identified as cis-miR-eQTL.

113 We sought to replicate our findings in a previous study using the same HTG EdgeSeq platform 114 by Nikpay et al. (9). Bonferroni correction was applied to address multiple testing (Online 115 Methods). There were 2,254 associations for 57 miRNAs with identical SNPs available in the replication cohort by Nikpay et al. (9). Additionally, 27 associations for six miRNAs were tested 116 117 for replication using proxy SNPs (Online Methods). There were 1,462 associations for 27 118 miRNAs replicated at Bonferroni-threshold (P<0.05/58) (Extended Data Fig. 2, Supplementary Tables 5-6). The effect estimates of replicated associations were strongly correlated (r=0.82, 119 120 P<2.2x10⁻¹⁶) (Extended Data Fig. 3a). Additionally, 1,719 associations were nominally 121 significant in Nikpay et al. (9), of which 1,685 (98%) were in a concordant direction 122 (Supplementary Table 6).

123

124 Replication of previously identified miR-eQTLs

125 In an alternative approach, we also attempted to replicate miR-eQTLs identified in previous

- studies (9,10). Associations reaching P<2.4x10⁻¹¹ in Nikpay et al. (9) were tested for replication 126
- 127 in our study (Extended Data Fig. 2), where 2,957 associations corresponding to 1,973 SNPs

128 and 34 miRNAs were replicated (P<0.05/52) with a significant correlation between effect 129 estimates (r=0.90, P<2.2x10⁻¹⁶) (Extended Data Fig. 3b). Additionally, we tested 8,820 cis and trans associations for 87 miRNAs that were previously reported by the Framingham Heart 130 131 Study (10) in our data. Of those, 1,320 associations for 29 miRNAs were replicated 132 (P<0.05/195) (Extended Data Fig. 3c). Collectively, 69% of associations in Nikpay et al. (20) 133 and 15% of associations in the Framingham Heart Study (19) were replicated in our study. 134 Altogether, our approaches successfully reported 4,310 associations pertaining to 64 miRNAs 135 which have been replicated across studies (Extended Data Fig. 2, Supplementary Table 7).

136

137 Functional annotation of miR-eQTLs

138 Using the Functional Mapping and Annotation (FUMA) (21), the identified and replicated miR-139 eQTLs were mapped into 22 loci (Fig. 2a). Over 70% of miR-eQTLs were located in the intronic 140 and intergenic regions (Fig. 2b, Supplementary Table 8). Out of 22 loci, 11 loci were 141 pleiotropic, i.e., linked to the level of multiple miRNAs. Fourteen loci regulated two miRNAs 142 and eight loci regulated more than two miRNAs (Supplementary Table 9). Highly pleiotropic 143 loci were identified in locus chr14:100655022-101244293, regulating 23 miRNAs (also known 144 as 14q32 miRNA cluster), the majority of which were cis-miR-eQTLs (98%). This locus was 145 mapped to RP11-566J3.2, RP11-638l2.4, YY1, YY1:RP11-638l2.2, SLC25A29, WDR25, 146 BEGAIN, DLK1, CTD-2644I21.1, LINC00523, RP11-566J3.4, and MEG3 (Extended Data Fig. 147 4). The locus in chr9:136128546-136296530 was mapped to ABO, ABO:RP11-430N14.4, 148 Y RNA, and LCN1P2 and regulated 18 miRNAs. This locus contained shared trans-miR-149 eQTLs for several well-known miRNAs, including miR-10, let-7, and miR-30 families 150 (Supplementary Table 9).

151 Associations between 296 SNPs residing in seed, mature, or precursor genes of miRNAs and 152 corresponding miRNAs were extracted from our GWAS results. Twelve associations were 153 significant at Bonferroni-threshold considering the number of unique SNPs (P<0.05/296), 154 consisting of three SNPs in the seed region of miR-4707-3p, miR-4482-5p, and miR-6891-3p, 155 three SNPs in mature region of miR-3130-3p, miR-6891-3p, and miR-6839-5p, and six SNPs 156 in precursor genes of six miRNAs. Additionally, 27 SNPs in 26 miRNAs were nominally 157 significant (Supplementary Table 10).

158

159 Heritability analysis

160 SNP-based heritability estimates for the plasma levels of 2,083 circulatory miRNAs were 161 obtained using massively expedited genome-wide heritability analysis (MEGHA) (22). The 162 distribution of heritability estimates is shown in Fig. 2c. Two miRNAs had a narrow-sense

163 heritability estimate greater than 0.7, namely miR-30e-5p (0.72) and miR-6511a-5p (0.70).

- 164 Twenty miRNAs had a narrow-sense heritability greater than 0.5, and 166 miRNAs had greater
- 165 than 0.3. Heritability estimates for all miRNA are shown in Supplementary Table 11. Repeating
- 166 the heritability analysis, including the first five principal components as covariates, resulted in
- 167 SNP-based heritability estimates with a Pearson correlation of 0.99 with estimates without the
- 168 principal components (Extended Data Fig. 5).

169 Cross-phenotype and multi-omics QTLs look-up

- As miRNAs dictate their role in biological processes by regulating the expression of their target
 genes, it is interesting to know whether miR-eQTLs are linked to the expression of other
- 172 genes, including their host and target genes. To explore this, we sought overlaps between
- 173 replicated miR-eQTLs and gene expression (eQTLs), protein (pQTLs), and metabolite-QTLs
- 174 (met-QTLs). We further checked if any of the genes or proteins that shared QTLs were target
- 175 genes of miRNAs.
- 176 Summary statistics for genetic variants that influence expression levels of mRNA transcripts 177 (cis and trans-eQTLs) in whole blood (N=31,684) were used to identify miR-eQTLs that affect 178 the expression of other genes (23). In this dataset, trans-eQTL analysis was conducted only 179 for SNPs previously identified in GWAS (23). Cis-miR-eQTLs for 39 miRNAs overlapped with 180 cis-eQTLs for 146 genes, 123 of which were protein-coding genes (Supplementary Table 12). 181 Twelve intragenic miRNAs shared cis-miR-eQTLs with their host genes (Supplementary Table 182 13). In addition, miR-136-5p resides within the intronic region of *RTL1* but had overlapping 183 cis-eQTLs with nearby genes, such as DLK1, WARS, BEGAIN, MEG3, and SLC25A29) 184 (Supplementary Table 12).
- Next, predicted target genes for miRNAs from TargetScan v7.2 (5) and experimentally validated target genes with robust validation methods (such as reporter assay, western blot or qRT-PCR) from miRTarBase (4) were retrieved to check whether miR-eQTLs overlap with eQTLs of their putative target genes. Twelve miRNAs shared either cis/trans-miR-eQTLs or cis/trans-eQTLs of their putative target genes (Supplementary Table 14). We identified shared trans-regulation by rs612169, located intronic to *ABO*, for miR-126-3p and its validated target *TCF4*.
- Protein-QTLs (pQTLs) summary results were used to identify miR-eQTLs affecting protein levels in the blood (24,25). Cis-miR-eQTLs of 18 miRNAs overlapped with pQTLs for nine proteins. Cis-miR-eQTLs for 14q32 miRNA cluster were shared with pQTLs of *DLK1* located in the nearby genomic region and *SEMG2* in a distant region of chromosome 20 (Fig. 3a, Supplementary Table 15). These included shared miR-eQTLs of six intragenic miRNAs, of which four miRNAs (miR-127-3p, miR-136-5p, miR-431-5p, and miR-433-5p) reside in *RTL1*.

198 Cis-miR-eQTLs of miR-625-5p overlapped with pQTLs for Alpha-(1,6)-fucosyltransferase, an 199 enzyme encoded by FUT8 gene where miR-625-5p resides. Cis-miR-eQTLs for miR-335-5p 200 that resides in *MEST* overlapped with Carboxypeptidase A4, encoded by *CBPA4* in a nearby 201 genomic region in chromosome 7. Trans-miR-eQTLs for 11 miRNAs overlapped with pQTLs 202 for 103 proteins (Fig. 3b, Supplementary Table 16). Of these, GNS was identified as common 203 predicted targets of let-7b-5p and let-7c-5p. Additionally, trans-miR-eQTLs of miR-145-5p and 204 miR-195-5p overlapped with eQTLs of their predicted target genes. For cardiovascular 205 proteins (25), cis-miR-eQTLs for miR-130a-3p overlapped with pQTLs of Pappalysin-1 206 (PAPPA). Overlap for trans-miR-QTLs was found with pQTLs of validated target genes of miR-207 126-3p (TEK) and miR-145-5p (MMP1 and VEGFA) (Supplementary Table 17). The overlap 208 of trans-miR-eQTLs between miR-143-3p and miR-145-5p with Dickkopf-related protein 1 209 (DKK1) were identified in both pQTLs datasets (24,25).

210 We used summary statistics from two common metabolomics platforms, Metabolon and 211 Nightingale, to identify miR-eQTLs affecting metabolic pathways by investigating plasma 212 levels of metabolites. Metabolon covers 529 metabolites (N=7,824) (26), while Nightingale 213 covers 123 metabolites in Kettunen et al. (N>20,000) (27) and 249 metabolites in the UK 214 Biobank (N=115,078) (28). Cis-miR-eQTLs for miR-1908-5p, miR-148a-3, miR-339-5p, and 215 miR-130a-3p overlapped with met-QTLs for 218 metabolites in both platforms. For example, 216 rs174561, located in the precursor gene of miR-1908-5p and intronic to FADS1, both known 217 to be associated with lipid and obesity traits, was associated with metabolites in Nightingale 218 that were also mainly lipid fractions. Trans-miR-eQTLs for nine miRNAs overlapped with four 219 unnamed metabolites in Metabolon (M32740, M33801, M36115, M36230), and 146 220 metabolites in the Nightingale platform (Supplementary Table 18).

221 Finally, GWAS Catalog was used to identify miR-eQTLs associated with complex traits (29). 222 At genome-wide significance, cis-miR-eQTLs were associated with GWAS traits, including 223 mental health, haematological indices, cancers, anthropometric measures, lipid levels, and 224 blood pressure (Supplementary Table 19). For example, cis-miR-eQTLs for miR-1908-5p 225 were associated with multiple traits, mainly lipid through FADS1, FADS2, or MYRF, supporting 226 the observed overlaps with eQTLs and pQTLs as described earlier. Trans-miR-eQTLs were 227 associated with different traits and diseases, including haematological indices, 228 cardiometabolic, cancer, and allergy. The pleiotropic regulatory region in chr9:136128546-229 136296530 consisted of trans-miR-eQTLs which were associated with protein and metabolite 230 levels and complex traits. For example, rs687289, intronic to ABO, was identified as trans-231 miR-eQTL for six miRNAs and overlapped with pQTLs, met-QTLs, and associated with GWAS 232 traits such as monocyte count, coagulation factor levels, and pancreatic cancer. Another

variant in *ABO*, rs644234, was associated with 40 protein biomarkers, including five
 cardiovascular proteins (Supplementary Table 20). This observation might suggest the
 relevance of miR-eQTLs in *ABO* to cardiovascular traits.

236 Phenome-wide association studies (PheWAS) in the UK-Biobank

We conducted phenome-wide association studies (PheWAS) in the UK Biobank (17) to investigate associations between genetically determined miRNA levels and a wide range of clinical conditions (Fig. 4a). The participants with genetic and hospital episode statistics data were used in the analysis. After excluding participants of non-European ancestries and one from each pair of related individuals, 423,419 individuals remained in the analysis (Extended Data Fig. 6). We tested the associations between genetically determined miRNA levels and 905 phecodes with at least 200 cases across 16 disease groups (Fig. 4b).

244 To extract genetic instruments for miRNAs, a threshold for cis-instruments at FDR<0.1 was 245 calculated across all SNPs residing ±500 kb of each miRNA. This threshold was chosen to 246 enable covering a higher number of miRNAs tested in PheWAS. At FDR<0.1, cis-instruments 247 were identified for 204 miRNAs. Weak instruments were filtered out using F-statistics>10 248 (Online Methods). After LD clumping (r^2 <0.1), a single cis-instrument was available for 85 249 miRNAs for which a single variant PheWAS were conducted (Supplementary Table 21). 250 Multiple cis-instruments were available to compute genetic risk scores (GRS) for 119 miRNAs 251 and test in GRS-PheWAS (Fig. 4a). Since each clinical diagnosis is not entirely independent 252 of the other, FDR correction was applied for each miRNA to account for multiple testing.

253 In the single variant PheWAS, 29 significant associations were identified between 9 SNPs and 254 23 clinical diagnoses at FDR<0.05 (Fig. 4a). Among these, rs2270197 (P=6.84x10⁻⁰⁵), rs55936521 (P=4.27x10⁻⁰⁶), rs5623708 (P=1.40x10⁻⁰⁵) and rs7130989 (P=7.16x10⁻⁰⁵) were 255 256 associated with hypertension. rs1254901, located 2KB upstream of VAMP5 and cis-miR-eQTL 257 for miR-6701, was associated with ischemic heart disease-related conditions, including 258 ischemic heart disease (P=6.51x10⁻⁰⁶). Rs2270197, intronic to *ITIH1* and cis-miR-eQTL for 259 miR-135a-5p, was associated with a range of clinical conditions, including osteoarthritis (P=4.22x10⁻⁰⁴), hypertension (P=6.84x10⁻⁰⁵), and bipolar disorders (P=4.02x10⁻⁰⁴) (Fig. 4c, 260 261 Supplementary Table 22).

In the genetic risk score (GRS) PheWAS, 44 associations between 17 cis-GRS and 24 diagnoses were identified at FDR<0.05 (Fig. 4a). The strongest association was identified between miR-1908-5p and benign neoplasm of colon (OR=0.96, P=1.99x10⁻⁰⁸) and cholelithiasis (OR=1.04, P=1.51x10⁻⁰⁵). Three miRNAs were associated with lower risk of obesity, namely miR-323b-3p (OR=0.97, P=2.28x10⁻⁰⁴), miR-329-3p (OR=0.97, P=1.12x10⁻

⁰⁴), and miR-543 (OR=0.97, P=1.20x10⁻⁰⁴). Three miRNAs were associated higher risk of skin 267 cancer, including miR-323b-3p (OR=1.05, P=4.79x10⁻⁰⁶), miR-376b-3p (OR= 1.04, 268 P=5.81x10⁻⁰⁵), and miR-379-5p (OR=1.05, P=7.68x10⁻⁰⁶) (Fig. 4d, Supplementary Table 22). 269 270 Out of 44 associations, extended-GRS was computed for 17 associations of five miRNAs with 271 genome-wide significant trans-miR-eQTLs, where all remained statistically significant in a 272 concordant direction (FDR<0.05) (Supplementary Table 23). Our PheWAS identified 73 273 associations between 45 clinical conditions and 26 miRNAs. Among those, 11 miRNAs were 274 associated with circulatory disorders (Fig. 5a). Several miRNAs were associated with clinical 275 diagnoses across different disease groups, indicating their pleiotropic properties, such as miR-276 323b-3p associated with endocrine/metabolic disease, infectious disease, and neoplasms 277 (Fig. 5b).

278

279 Mendelian randomisation

280 Mendelian randomisation (MR) was conducted for miRNAs with at least three independent 281 instruments (Online Methods). Thirty-seven associations for 14 miRNAs with at least three 282 instruments were tested in MR-PheWAS (Fig. 4a). The same cis or extended instruments for 283 miRNAs were used in MR-PheWAS with effect estimates from the Rotterdam Study 284 (N=2,178), whereas genetic associations with the outcomes were taken from the UK-Biobank 285 (N=423,419). All 37 tested associations were significant in MR Inverse variance weighted 286 (IVW) (FDR<0.05), had no indication of pleiotropy or heterogeneity and were in concordant 287 direction with MR-Egger or Weighted Median (WM) (P<0.05) (Supplementary Table 24). 288 Among those, the strongest association was observed between miR-1908-5p and the risk of 289 benign neoplasm of the colon (MR-IVW estimate=-0.40, P=3.9×10⁻¹⁰). Six miRNAs were 290 associated with a higher risk of melanoma, including miR-329-3p (MR-IVW estimate=0.37, 291 P=5.4×10⁻⁹), miR-376b-3p (MR-IVW estimate=0.39, P=3.0×10⁻⁸), miR-323b-3p (MR-IVW 292 estimate=0.44, P=1.4×10⁻⁷), and miR-379-5p (MR-IVW estimate=0.47, P=1.5×10⁻⁵). All 37 293 associations were significant when the correlation matrix between instruments was added, 294 with no outliers detected by MRPRESSO. Of 37, 13 associations had genome-wide significant 295 trans-miR-eQTLs to conduct extended-MR as a replication. For the remaining 24 associations, 296 concordant direction across different MR methods was observed (Fig. 5c).

297 Extended-MR was conducted for 13 associations by adding genome-wide significant trans-298 miR-eQTLs. Twelve associations were significant (MR-IVW FDR<0.05) with no indication of 299 pleiotropy and supported by MR-Egger or WM (P<0.05) (Supplementary Table 25). Nine 300 associations from MR-PheWAS had genetic association data available in large GWAS for 301 coronary artery disease, body mass index (BMI) and waist to hip ratio (WHR) (30-32) (Fig. 302 5a). Two associations were replicated between miR-543 and WHR (MR-IVW estimate=-0.02,

P=1.72×10⁻⁰²) and between miR-329-3p and BMI (MR-IVW estimate=-0.03, P=1.89×10⁻⁰²), 303

304 both in the same protective effects as in MR-PheWAS (Table 1, Extended Data Fig. 7,

305 Supplementary Table 26). Reverse MR analyses were conducted for BMI and WHR as risk 306 factors on miR-543 and miR-329-3p as the outcomes, where no significant effects in the 307 opposite directions were observed (Supplementary Table 27).

308

309 Target genes and enrichment analysis

310 An in-silico search of target genes using TargetScan v7.2 and miRTarBase (5,33) identified 311 eighty-two predicted and eighteen validated target genes of miR-543 associated with BMI or 312 WHR. Forty-three predicted and fifty-eight validated target genes for miR-329-3p were also 313 associated with BMI or WHR. Eighteen target genes were in common between miR-543 and 314 miR-329-3p, where eleven genes were validated targets for at least one of them, including 315 BRCH1 and TNRC6B as validated targets of both miRNAs (Supplementary Table 28). 316 Enrichment analysis was conducted as described in our previous work (34), resulting in a 317 significant enrichment for BMI or WHR-related genes among validated targets of miR-543 318 (P=9.00x10⁻⁰³) and predicted targets of miR-329-3p (P=3.18x10⁻⁰²).

319

320 Discussion

321 We present a genome-wide identification of miR-eQTLs using the next-generation sequencing 322 method in 2,178 individuals in the population-based Rotterdam Study cohort. This study is 323 currently the most extensive single-site analysis of 2,083 circulatory miRNA levels in a 324 population of European ancestries. We discovered 3,292 genetic associations for 63 miRNAs. 325 The highest proportion of variance explained was observed for miR-625-5p (11%) by 326 rs2127868 (P=1.63x10⁻⁶⁰), in perfect LD with rs2127870 associated with the level of miR-625-5p in plasma (P=2.9x10⁻²⁶⁰) and whole blood (P=2.98x10⁻⁰⁹) (9,10). Altogether, 4,310 genetic 327 328 associations for 64 miRNAs were replicated across different studies, including trans-miR-329 eQTLs, whose replication was previously minimal. Genetically proxied miRNAs were tested 330 against a wide range of clinical conditions in the UK-Biobank, suggesting the pleiotropic 331 properties of several miRNAs by being associated with clinical outcomes. Such observation is 332 expected, given that miRNAs could potentially regulate many genes that are involved in 333 different molecular pathways (4,5). Our MR analysis identified the potentially causal role of 334 miRNAs in various complex traits and disorders.

We showed that miR-eQTLs overlap with gene expression QTLs and protein QTLs of their 335 336 target genes, supporting their role in translational repression. Since target genes tend to be 337 clustered to miRNAs according to their function (34,35), these shared miR-eQTLs might have

338 biological relevance. Cis-miR-eQTLs that overlap with trans-mRNA-eQTLs might point to the 339 downstream regulatory effect from miRNAs to their (direct or indirect) target genes. When cis-340 mRNA-eQTLs overlap with trans-miR-eQTLs, the effect might be going from the genes to 341 miRNAs, pointing to bidirectional interaction between miRNAs and target genes as a feedback 342 mechanism (36,37). However, when trans-miR-eQTLs overlap with trans-mRNA-eQTLs, a 343 third factor may have contributed to simultaneous changes in miRNA and gene expression. 344 As an example, a genetic variant could affect the regulatory region shared between miRNA 345 and a gene that are co-expressed. We also hypothesise that cis- and trans-miR-eQTLs might 346 have different clinical relevance. The magnitude of associations between miRNAs and 347 complex traits appeared closer to the null when trans-miR-eQTLs were added as instruments. 348 Trans-miR-eQTLs might affect the stability of mature miRNAs, whereas cis-miR-eQTLs 349 influence the hairpin structure and regulate the expression of primary miRNAs (9).

350 The current analysis identified co-expression of miRNAs and host genes, which could occur 351 through modification of promoter activity, chromatin accessibility, transcription factor binding, 352 or DNA methylation (10). However, many miRNAs also have their own promoters (38), and 353 the association could be independent of the host genes (10,39). This finding deepens our 354 understanding that the relationship between miRNAs and gene expressions is more 355 commonly driven by genetics (40). The genetic effect might be less strong for miRNAs than 356 mRNAs (12,13), as shown by the small variation explained by miR-eQTLs, which could act as 357 a mechanism to maintain biological function during evolution.

358 Given that each miRNA potentially regulates multiple target genes and pathways (1,2,5), even 359 small changes in miRNA expression could result in considerable consequences. This concept 360 aligns with the strong evolutionary constraint on miRNAs and their binding sites in gene 3-UTRs in humans and other species (5). Moreover, the seed, mature, and precursor regions of 361 362 miRNA genes are known to have a lower density of genetic variation than the whole genome 363 (41). Our study shows that the genetic variants in those regions could have functional 364 importance, such as affecting miRNA expression. This functional consequence occurs by 365 interfering with the processing of precursor to mature miRNA or the interaction between 366 mature miRNA and target genes, resulting in gain and loss of function, which could deregulate 367 biological pathways (42,43).

Human miRNAs can be categorised into families with similar functions due to their conserved structures in the mature or seed sequences (44) and clusters when they are encoded from the same region in our genome (3). Here, we showed that the 14q32 miRNA cluster shares cisregulatory variants. We also showed that multiple miRNAs are regulated by shared miReQTLs (45), such as the pleiotropic trans-miR-eQTLs in the *ABO* gene. Several families

sharing trans-regulatory variants in *ABO*, such as miR-10 family, miR-30 family, let-7 family,
and miR-139-5p, were well-known in cardiometabolic traits and cancers (46-48). This finding
agrees with the concept that several miRNAs can work in networks to control gene expression
and pathways underlying diseases (49).

377 Several associations with complex traits highlighted in this study were reported in the 378 literature. For example, miR-543 was released in plasma following a high-fat diet (50), which 379 could be a physiological response to reduce the risk of obesity. Target genes of miR-329-3p 380 were involved in lipid and glucose metabolism in rats (51). Low miR-329 expression was 381 observed in melanoma cells, while miR-329 mimics could suppress the progression of 382 melanoma (52). The effect in tumour tissue for miR-329 and miR-1908-5p (14,52) was 383 opposite compared to our MR analysis which better captures the lifetime effect of miRNAs. 384 This suggests the changes in the level of miRNAs in tumour tissue might be the consequence 385 of disease processes and supports the hypothesis that the dysregulation of miRNA in diseased 386 tissue might arise from negative feedback by downstream genes (36,37). It is also possible 387 that the genetic effects have been buffered by canalisation (19), where people with a 388 genetically higher level of miRNAs since the intra-uterine period might be resistant to the effect 389 of higher miRNAs throughout life.

390 Here we would like to underline several aspects to be considered when attempting to replicate 391 miR-eQTLs across studies. First, we found fewer trans were replicated than cis-miR-eQTLs. 392 as observed in the large eQTL analysis (53). Trans-eQTLs are known to have weaker effects, 393 are less replicable, and are more tissue-specific (54-56) than cis-eQTLs. Second, the 394 concordant direction with those reported by Nikpay et al. (9) suggested that the type of 395 biological sample and profiling method could have an effect. The lower replication rate in the 396 Framingham Heart Study is likely due to differences in type of sample (whole blood vs 397 plasma), as previously reported (57). Third, one should consider any systematic difference in participants' characteristics across studies. This study came from a population-based cohort 398 399 which makes the findings more generalisable. Other studies were in obese individuals (9) or 400 enriched for a specific disease (11), making it particularly useful for investigating the relevant 401 disease but not for a wide range of complex traits and disorders. Finally, since the overall 402 proportion of variation explained by each miR-eQTL is relatively small, larger GWAS for miR-403 eQTLs identification will be a valuable resource to enrich the genetic studies on miRNAs. In 404 particular, incorporating diverse ancestries could generate more transferrable findings for a 405 wider population.

406 Collectively, the integration of genomics, molecular, and clinical data in this study has provided 407 a better understanding of the genetic regulation of miRNAs and allowed us to perform a

- 408 systematic investigation on the effect of perturbations of plasma miRNA levels on a wide range
- 409 of clinical conditions. As an example, we highlight miR-543 and miR-329-3p associated with
- obesity-related traits with potential downstream targets. Although it is unlikely a single miRNA 410
- 411 or its target genes will be entirely responsible for the disease mechanisms, it is plausible that
- 412 the effect of identified miRNAs to be mediated at least in part through those target genes. Our
- 413 approach allows generating testable hypotheses for further functional and clinical studies to
- 414 dissect the underlying molecular and cellular pathways of various traits and diseases.
- 415 The summary statistics for miR-eQTLs identified in our study and their link to other omics 416 layers and their associations with various clinical outcomes will be available through a web 417 tool called miRNomics Atlas (www.mirnomicsatlas.com). This web tool allows the use of genetic association data of miR-eQTLs, serving as valuable resources for future research to 418 419 decipher the association and causal role of miRNAs in human diseases and their regulatory 420 pathways.
- 421

422

423 Online Methods

424 Cohort description

425 The Rotterdam Study (RS) is a large prospective population-based cohort study among 426 middle-aged and elderly in the suburb Ommoord in Rotterdam, the Netherlands. In 1990, 427 7,983 inhabitants aged 55 years old and older were recruited to participate in the first cohort 428 (RS-I). In 2000, the study was extended with a second cohort of 3,011 participants (RS-II) who 429 became 55 years old or moved into the study district since the beginning of the study. In 2006, 430 a further extension of the cohort (RS-III) was initiated, including 3,932 participants aged 45-431 54 years. In 2016, the recruitment of another extension started (RS-IV), targeting participants 432 aged 40 years and over, adding 3,005 new participants. A detailed description of the 433 Rotterdam Study can be found elsewhere (20).

434 Circulatory miRNA levels

435 Plasma miRNA levels were determined using the HTG EdgeSeg miRNA Whole Transcriptome 436 Assay (WTA) to quantitatively detect the expression of 2.083 human miRNAs transcripts (HTG 437 Molecular Diagnostics, Tuscon, AZ, USA) and using the Illumina NextSeq 500 sequencer 438 (Illumina, San Diego, CA, USA). This method characterises miRNA expression patterns and 439 measures the expression of 13 housekeeping genes to allow flexibility during data 440 normalisation and analysis. Quantification of miRNA expression was based on counts per 441 million (CPM). Log2 transformation of CPM was used as standardisation and adjustment for 442 total reads within each sample. MiRNAs with log2 CPM <1.0 were indicated as not expressed 443 in the samples.

444 Genotype data

445 At baseline, blood was drawn for genotyping from 6,291 participants in RS-I, 2,157 in RS-II, 446 and 2,654 in RS-IV. Genotyping in RS-I-II was performed using the HumanHap550 Duo 447 BeadChip (Illumina, San Diego, California) for RS-I-II and the Global Screening Array 448 (GSAMD-v3) Illumina array for RS-IV. Samples with a call rate below 97.5%, gender 449 mismatches, excess autosomal heterozygosity, duplicates or family relations, and ethnic 450 outliers were excluded. Variants with call rates below 95.0%, failing missingness test, Hardy-Weinberg equilibrium P<10⁻⁶, and allele frequency below 1% were removed. Genotypes were 451 452 imputed using the MaCH/minimac software to the 1000 Genomes phase I version 3 reference 453 panel or phase 3 version 5 reference panels (for RS-IV). Genetic variants with minor allele 454 frequency < 0.05 and imputation quality < 0.7 were filtered out after genotype imputation.

455 Genome-wide association studies

Genome-wide association studies (GWAS) were conducted for 2,083 miRNAs in 2,178 456 457 participants randomly selected from three sub-cohorts of the Rotterdam Study to identify 458 miRNA-expression quantitative trait loci (miR-eQTLs). Given the high number of miRNAs, 459 GWAS was performed within the high-dimensional analysis framework (HASE) to reduce the computational burden and enable efficient implementation of GWAS on thousands of 460 461 phenotypes (58). Multiple linear regression was used to test for association between each genetic variant and miRNA level, with miRNA level as the outcome and expected genotype 462 463 count from imputation as predictors, with adjustment for age, sex, sub-cohort, and the first five 464 principal components to account for population stratification.

We used the genome-wide threshold of $P<5\times10^{-08}$ and Bonferroni-corrected for 2,083 miRNAs 465 (P<2.4x10⁻¹¹) to identify significant associations. Associations reaching significance in the 466 467 Rotterdam Study were taken forward for replication in a published miR-eQTLs study by Nikpay 468 et al. (9) using the SNPs or their proxy SNPs ($r^2>0.7$ within 500kb on either side of lead SNP 469 position) obtained using LDlinkR (59). Linkage disequilibrium (LD) pruning was used to identify 470 the number of independent SNPs for each miRNA (r²<0.01). Similarly, associations identified 471 in previous GWAS by Nikpay et al. (at P<2.4x10⁻¹¹) (9) and Huan et al. in the Framingham 472 Heart Study (at FDR<0.1) (10) were also tested for replication. The Bonferroni threshold was 473 used for replication (α <0.05/n, where n is the total number of SNP-miRNA pairs after pruning). 474 Replication was defined when the associations between SNP and miRNA were Bonferroni-475 significant in an independent cohort with a concordant direction of effect.

476 Functional annotation of miR-eQTLs

477 Genomic miRNAs miRBase v20 coordinates of were extracted from 478 (ftp://mirbase.org/pub/mirbase/20/genomes/has.gff3) (3). Both SNPs and mature miRNA 479 positions were based on Genome Reference Consortium Human Build 37 (GRCh37). The 480 position of each miR-eQTL was mapped as cis or trans with respect to the miRNA position. 481 SNPs located ±500kb upstream and downstream of the start position of mature miRNAs were 482 identified as cis, and those located more than ±500kb away were identified as trans. To identify SNPs in seed, mature, or precursor genes of miRNA, the database was downloaded from 483 http://bioinfo.life.hust.edu.cn/miRNASNP/#!/download (60). 484

The web-based tool Functional Mapping and Annotation (FUMA) was used to annotate identified miR-eQTLs. A detailed description of the FUMA workflow is described elsewhere (21). Independent significant miR-eQTLs were defined as those with $P<5\times10^{-08}$ in the discovery GWAS or those replicated in independent cohorts and moderate LD with each other at r²<0.6. LD calculation was referenced based on the 1000 Genomes phase 3 panel. These

It is made available under a CC-BY-NC 4.0 International license.

490 SNPs were further clumped to lead SNPs ($r^2 < 0.1$). Genomic risk loci were then defined based 491 on the lead SNPs when they overlap with a maximum distance of 250kb between LD blocks. 492 The major histocompatibility complex (MHC) region was excluded using the default region 493 between *MOG* and *COL11A2* genes (21,61).

494 Heritability analysis

The SNP-based heritability estimates for 2,083 circulatory miRNAs were obtained using massively expedited genome-wide heritability analysis (MEGHA) (22). A genetic relationship matrix was constructed from 1000 Genome imputed genotypes filtered on imputation quality (<0.5) and allele frequency (<0.1) using GCTA (62). After applying a stringent cut-off of 0.025 for genetic relatedness, 1,506 individuals were used for heritability estimation. Using MEGHA, the genetic relationship matrix, and age and sex as covariates, we computed the heritability and uncertainty (p-values based on 1000 permutations).

502

503 Cross-phenotype and quantitative trait loci look-up

Cross-phenotype and quantitative trait loci look-up leveraged replicated miR-eQTLs with 504 505 summary statistics for gene expression (eQTLs), protein-QTLs (pQTLs), metabolite-QTLs 506 (met-QTLs), and complex traits. Summary for cis and trans-eQTLs analysis in whole blood 507 were downloaded from <u>https://www.eqtlgen.org/index.html</u> (23). Summary statistics for pQTLs 508 were from https://www.phpc.cam.ac.uk/ceu/proteins/ (24) and the SCALLOP consortium 509 available through https://zenodo.org/record/2615265/ (25). Summary statistics for met-QTLs 510 (http://metabolomics.helmholtz-muenchen.de/gwas/) were from Metabolon (26) and 511 Nightingale from a published study (http://www.computationalmedicine.fi/data/NMR_GWAS/) 512 (27) and in the UK Biobank available through OpenGWAS project (https://gwas.mrcieu.ac.uk) 513 database for intragenic miRNAs was from (28). The https://bmi.ana.med.uni-514 (63). downloaded muenchen.de/miriad/ GWAS Catalog was from 515 https://www.ebi.ac.uk/gwas/docs/file-downloads (29).

516 Phenome-wide association studies

517 To investigate associations between genetically determined circulatory miRNA and a wide 518 range of clinical diagnoses, a phenome-wide association study (PheWAS) was performed 519 using hospital episode statistics data in the UK Biobank, a large prospective cohort study with 520 over 500,000 individuals aged 40-69 years old recruited between 2006-2010 (17). In brief, 521 participants with genotype and phenotype data were considered in the analysis. Quality control 522 steps taken in the UK Biobank has been described elsewhere. Our analysis was restricted to 523 participants who identified themselves as "White". One from each pair of relatives and 524 withdrawn individuals as of August 2021 were excluded (Extended Data Fig. 3). ICD (ninth

and tenth editions) codes from the hospital episode statistics data were aligned into phecodes
to identify clinically related phenotypes. The analysis was limited to phecodes with at least 200
cases to allow sufficient power for MR analysis (64). PheWAS was conducted using the
PheWAS package in R (65).

For each miRNA, associations for genetic variants residing in 500kb on either side of the miRNA position (cis-SNPs) were extracted. The false discovery rate (FDR) was calculated across all cis-SNPs for each miRNA, where those with FDR<0.1 were selected as cis instruments (18). Trans-SNPs associated with circulatory miRNA at P<5x10⁻⁰⁸ were added as trans instruments in the sensitivity analysis. Instruments were filtered for F-statistics> 10 to avoid weak instrument bias (66). Linkage disequilibrium (LD) clumping for the instruments was conducted using a threshold of $r^2 < 0.1$ and a window of 10,000 kb.

For miRNA with single cis miR-eQTL satisfying the instrument criteria, cis-SNP was used as the proxy for corresponding miRNA in single-variant PheWAS. For miRNAs with multiple independent miR-eQTLs, weighted genetic risk scores (GRS) were computed for individuals in the UK Biobank as the sum score of miRNA-increasing alleles of miR-eQTLs identified in the Rotterdam Study using effect sizes as their weights as implemented using PLINK (36). The weighted GRS was rescaled by subtracting GRS from its mean and dividing by its standard deviation to express the association per-SD of the miRNA-increasing allele.

In the main analysis, GRS for each miRNA (miRNA-GRS) was computed from cis-miR-eQTLs (cis-GRS). Additionally, trans-miR-eQTLs at genome-wide significant (P<5x10⁻⁰⁸) were added, in an extended analysis, to validate findings from cis-GRS. Multiple logistic regression was performed in the UK Biobank for each miRNA-GRS with adjustment for age, sex, genotyping array, and the first five principal components to account for population stratification. Given each phecode is not independent of the other, the false discovery rate (FDR) was calculated for each miRNA-GRS to account for multiple testing (67).

550 Mendelian randomisation

551 Following PheWAS, two-sample Mendelian randomisation (MR) analysis was conducted to 552 assess the causal relationship between candidate miRNAs and outcomes of interest identified 553 from PheWAS. MR-PheWAS considered miRNAs with three or more independent instruments 554 to enable performing robust MR methods as sensitivity analysis. The same set of genetic 555 instruments used in PheWAS contributed to the exposure data in MR-PheWAS. The level of 556 each candidate miRNA was rescaled by subtracting the value from its mean and dividing by 557 its standard deviation (SD) to express the association per-SD increase of the miRNA level. 558 The genetic association between the instruments and the outcome was taken from the UK 559 Biobank. Associations that were significant at FDR<0.05 from MR-PheWAS were taken

560 forward for validation using genetic association estimates (outcome data) from large GWAS 561 consortia or by adding genome-wide significant trans-miR-eQTLs in an extended-MR.

562 The multiplicative random effect inverse variance weighted method (IVW) was used in the 563 main analysis to combine the effect estimates of the genetic instruments assuming all 564 instruments are valid (68). FDR adjustment was calculated for each miRNA based on p-values 565 of MR-IVW since it was considered the most powerful method when all instruments are valid 566 (68). Robust MR methods which allow the inclusion of pleiotropic variants were used as a 567 sensitivity analysis, including weighted median (WM) or MR-Egger (69-71). WM estimate is 568 valid if less than half of the weight of the genetic instrument is free from horizontal pleiotropy. 569 MR-Egger does not force the regression line through an intercept of zero, making it statistically 570 inefficient but provides a causal estimate corrected for directional horizontal pleiotropy. A non-571 null intercept in MR-Egger indicates evidence of pleiotropy (70). The agreement among 572 different MR methods was examined to support a robust estimation of causal effects.

573 Since a liberal LD threshold ($r^2 < 0.1$) was used for clumping, a further sensitivity analysis was 574 conducted by incorporating the correlation matrix between genetic instruments in the fixed 575 effect IVW method. MRPRESSO was used to detect outliers (72) and MR analysis was 576 repeated after excluding outliers. Results for MR analysis using different MR methods were 577 presented as forest plots. For replicated associations, reverse MR was conducted to assess 578 the directionality of associations. Independent genetic instruments for complex traits 579 (r²<0.001) were identified from large GWAS consortia for the outcomes of interest. 580 Associations between the genetic instruments for complex traits with candidate miRNA levels 581 were extracted from the Rotterdam Study.

582 Target genes and enrichment analysis

To identify putative target genes for miRNAs, predicted and validated target genes of miRNAs 583 584 were retrieved from TargetScan v7.2 and miRTarBase (4,5). For enrichment analysis, genes 585 with predicted miRNA-target interaction (MTI) in TargetScan or validated MTI, including weak 586 and strong validation methods in miRTaRBase, were considered. SNPs reaching genome-587 wide significance in large consortia GWAS for significant traits were mapped into protein-588 coding genes where they reside. Of those, predicted and validated target genes of miRNAs 589 were identified. The enrichment analysis was conducted to test if the target genes of candidate 590 miRNAs are enriched for the associated traits, as described in our previous work (34). 591 Enrichment analysis was performed separately for predicted and validated target genes.

- 592
- 593

594 Acknowledgements

595 We would like to thank all participants of the Rotterdam Study and the UK Biobank. The Rotterdam Study is supported by the Erasmus MC University Medical Center and Erasmus 596 597 University Rotterdam; The Netherlands Organisation for Scientific Research (NWO); The 598 Netherlands Organisation for Health Research and Development (ZonMw); the Research 599 Institute for Diseases in the Elderly (RIDE): The Netherlands Genomics Initiative (NGI): the 600 Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the 601 European Commission (DG XII); and the Municipality of Rotterdam. The UK Biobank has 602 approval from the North-West Multi-centre Research Ethics Committee (MREC) as a 603 Research Tissue Bank (RTB) approval. Explicit informed consent was obtained from all 604 participants when they enrolled in the UK Biobank. Access to the UK Biobank was provided 605 through application 52569. This work was enabled by the computing resources and support from the Imperial College Research Computing Service and Erasmus MC. We thank Loukas 606 607 Zagkos for helping with the visualisation of the results.

608 RM is supported by the President's PhD Scholarship from Imperial College London. AD is 609 funded by a Wellcome Trust seed award (206046/Z/17/Z). This project is partly supported by 610 the Erasmus MC Fellowship (EMCF20213) and Alzheimer Nederland (WE.03-2021-10) grants 611 of MG. PE acknowledges support from the Medical Research Council (MR/S019669/1) for the 612 MRC Centre for Environment and Health, the British Heart Foundation (RE/18/4/34215) for 613 the Imperial BHF Centre for Research Excellence, the UK Dementia Research Institute 614 (MC PC 17114) and the National Institute for Health Research Imperial College Biomedical 615 Research Centre for infrastructure support. 616

617 Code availability

For statistical analyses, we used the following software High-Dimensional Analysis
Framework (HASE) (<u>https://github.com/roshchupkin/hase</u>), R version 3.6.3 (<u>https://www.r-</u>
project.org), Plink v1.9 (https://www.cog-genomics.org/plink/), FUMA v1.4.1
(<u>https://fuma.ctglab.nl/</u>).

622

623

624

625 References

- 626 (1) Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell.* 2004; 116627 (2): 281-297.
- 628 (2) Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell.* 2009; 136 (2):
 629 215-233.
- 630 (3) Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to 631 function. *Nucleic acids research.* 2019; 47 (D1): D155-D162.
- (4) Huang H, Lin Y, Li J, Huang K, Shrestha S, Hong H, et al. miRTarBase 2020: updates to
 the experimentally validated microRNA-target interaction database. *Nucleic acids research*.
 2020; 48 (D1): D148-D154.
- 635 (5) Agarwal V, Bell GW, Nam J, Bartel DP. Predicting effective microRNA target sites in 636 mammalian mRNAs. *elife.* 2015; 4 e05005.

637 (6) Grasedieck S, Sorrentino A, Langer C, Buske C, Döhner H, Mertens D, et al. Circulating
638 microRNAs in hematological diseases: principles, challenges, and perspectives. *Blood, The*639 *Journal of the American Society of Hematology.* 2013; 121 (25): 4977-4984.

- 640 (7) Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: From cells to 641 clinic. *Trends in Genetics.* 2022; .
- (8) Garcia-Martin R, Wang G, Brandão BB, Zanotto TM, Shah S, Kumar Patel S, et al.
 MicroRNA sequence codes for small extracellular vesicle release and cellular retention. *Nature*. 2022; 601 (7893): 446-451.

(9) Nikpay M, Beehler K, Valsesia A, Hager J, Harper M, Dent R, et al. Genome-wide
identification of circulating-miRNA expression quantitative trait loci reveals the role of several
miRNAs in the regulation of cardiometabolic phenotypes. *Cardiovascular research.* 2019;
115 (11): 1629-1645.

- (10) Huan T, Rong J, Liu C, Zhang X, Tanriverdi K, Joehanes R, et al. Genome-wide
 identification of microRNA expression quantitative trait loci. *Nature communications.* 2015; 6
 (1): 1-9.
- (11) Akiyama S, Higaki S, Ochiya T, Ozaki K, Niida S, Shigemizu D. JAMIR-eQTL: Japanese
 genome-wide identification of microRNA expression quantitative trait loci across dementia
 types. *Database*. 2021; 2021 (2021): baab072.
- (12) Civelek M, Hagopian R, Pan C, Che N, Yang W, Kayne PS, et al. Genetic regulation of
 human adipose microRNA expression and its consequences for metabolic traits. *Human molecular genetics*. 2013; 22 (15): 3023-3037.
- (13) Lappalainen T, Sammeth M, Friedländer MR, Ac't Hoen P, Monlong J, Rivas MA, et al.
 Transcriptome and genome sequencing uncovers functional variation in humans. *Nature*.
 2013; 501 (7468): 506-511.
- (14) Sonehara K, Sakaue S, Maeda Y, Hirata J, Kishikawa T, Yamamoto K, et al. Genetic
 architecture of microRNA expression and its link to complex diseases in the Japanese
 population. *Human molecular genetics.* 2021; .

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

664 (15) Brown RA, Epis MR, Horsham JL, Kabir TD, Richardson KL, Leedman PJ. Total RNA extraction from tissues for microRNA and target gene expression analysis: not all kits are 665 666 created equal. BMC biotechnology. 2018; 18 (1): 1-11.

(16) Godoy PM, Barczak AJ, DeHoff P, Srinivasan S, Etheridge A, Galas D, et al. 667 668 Comparison of reproducibility, accuracy, sensitivity, and specificity of miRNA quantification 669 platforms. Cell reports. 2019; 29 (12): 4212-4222. e5.

(17) Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an 670 671 open access resource for identifying the causes of a wide range of complex diseases of 672 middle and old age. Plos med. 2015; 12 (3): e1001779.

673 (18) Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. 674 PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease 675 associations. Bioinformatics. 2010; 26 (9): 1205-1210.

676 (19) Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology 677 contribute to understanding environmental determinants of disease? International journal of 678 epidemiology. 2003; 32 (1): 1-22.

679 (20) Ikram MA, Brusselle G, Ghanbari M, Goedegebure A, Ikram MK, Kavousi M, et al. 680 Objectives, design and main findings until 2020 from the Rotterdam Study. European journal 681 of epidemiology. 2020; 1-35.

682 (21) Watanabe K, Taskesen E, Van Bochoven A, Posthuma D. Functional mapping and 683 annotation of genetic associations with FUMA. Nature communications. 2017; 8 (1): 1-11.

684 (22) Ge T, Nichols TE, Lee PH, Holmes AJ, Roffman JL, Buckner RL, et al. Massively 685 expedited genome-wide heritability analysis (MEGHA). Proceedings of the National 686 Academy of Sciences. 2015; 112 (8): 2479-2484.

687 (23) Võsa U, Claringbould A, Westra H, Bonder MJ, Deelen P, Zeng B, et al. Unraveling the 688 polygenic architecture of complex traits using blood eQTL metaanalysis. *BioRxiv.* 2018; 689 447367.

(24) Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic 690 691 atlas of the human plasma proteome. Nature. 2018; 558 (7708): 73-79.

(25) Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, et al. 692

693 Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. 694 Nature metabolism. 2020; 2 (10): 1135-1148.

695 (26) Shin S, Fauman EB, Petersen A, Krumsiek J, Santos R, Huang J, et al. An atlas of 696 genetic influences on human blood metabolites. Nature genetics. 2014; 46 (6): 543-550.

697 (27) Kettunen J, Demirkan A, Würtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide 698 study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. 699 Nature communications. 2016; 7 (1): 1-9.

700 (28) Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU 701 OpenGWAS data infrastructure. BioRxiv. 2020; .

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

702 (29) Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The 703 NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays 704 and summary statistics 2019. Nucleic acids research. 2019; 47 (D1): D1005-D1012.

705 (30) Nelson CP, Goel A, Butterworth AS, Kanoni S, Webb TR, Marouli E, et al. Association 706 analyses based on false discovery rate implicate new loci for coronary artery disease. 707 Nature genetics. 2017; 49 (9): 1385.

- 708 (31) Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-709 analysis of genome-wide association studies for height and body mass index in \sim 700000 710 individuals of European ancestry. Human molecular genetics. 2018; 27 (20): 3641-3649.
- 711 (32) Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New 712 genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015; 518 713 (7538): 187-196.
- 714 (33) Hsu S, Lin F, Wu W, Liang C, Huang W, Chan W, et al. miRTarBase: a database
- 715 curates experimentally validated microRNA-target interactions. Nucleic acids research. 716 2011; 39 (suppl 1): D163-D169.
- 717 (34) Mustafa R, Ghanbari M, Evangelou M, Dehghan A. An enrichment analysis for
- 718 cardiometabolic traits suggests non-random assignment of genes to microRNAs.
- 719 International journal of molecular sciences. 2018; 19 (11): 3666.

720 (35) Sakaue S, Hirata J, Maeda Y, Kawakami E, Nii T, Kishikawa T, et al. Integration of 721 genetics and miRNA-target gene network identified disease biology implicated in tissue 722 specificity. Nucleic acids research. 2018; 46 (22): 11898-11909.

723 (36) Melling GE, Flannery SE, Abidin SA, Clemmens H, Prajapati P, Hinsley EE, et al. A 724 miRNA-145/TGF-B1 negative feedback loop regulates the cancer-associated fibroblast 725 phenotype. Carcinogenesis. 2018; 39 (6): 798-807.

726 (37) Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. MicroRNA regulation of a 727 cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. 728 Proceedings of the National Academy of Sciences. 2008; 105 (50): 19678-19683.

- 729 (38) Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, et al. Chromatin structure 730 analyses identify miRNA promoters. Genes & development. 2008; 22 (22): 3172-3183.
- 731 (39) Borel C, Deutsch S, Letourneau A, Migliavacca E, Montgomery SB, Dimas AS, et al. 732 Identification of cis-and trans-regulatory variation modulating microRNA expression levels in 733 human fibroblasts. Genome research. 2011; 21 (1): 68-73.
- 734 (40) Gamazon ER, Ziliak D, Im HK, LaCroix B, Park DS, Cox NJ, et al. Genetic architecture 735 of microRNA expression: implications for the transcriptome and complex traits. The 736 American Journal of Human Genetics. 2012; 90 (6): 1046-1063.
- (41) Cammaerts S, Strazisar M, De Rijk P, Del Favero J. Genetic variants in microRNA 737 738 genes: impact on microRNA expression, function, and disease. Frontiers in Genetics. 2015; 739 6 186.
- 740 (42) Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the
- 741 implications for cancer research. Nature Reviews Cancer. 2010; 10 (6): 389-402.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 742 (43) Goulart LF, Bettella F, Sønderby IE, Schork AJ, Thompson WK, Mattingsdal M, et al. 743 MicroRNAs enrichment in GWAS of complex human phenotypes. BMC genomics. 2015; 16 744 (1): 1-10.
- 745 (44) Kaczkowski B, Torarinsson E, Reiche K, Havgaard JH, Stadler PF, Gorodkin J. 746 Structural profiles of human miRNA families from pairwise clustering. *Bioinformatics*. 2009; 25 (3): 291-294. 747
- 748 (45) Somel M, Guo S, Fu N, Yan Z, Hu HY, Xu Y, et al. MicroRNA, mRNA, and protein 749 expression link development and aging in human and macague brain. Genome research. 750 2010; 20 (9): 1207-1218.
- (46) Duell EJ, Lujan-Barroso L, Sala N, Deitz McElyea S, Overvad K, Tjonneland A, et al. 751 752 Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. 753 International journal of cancer. 2017; 141 (5): 905-915.
- 754 (47) Mens MM, Maas SC, Klap J, Weverling GJ, Klatser P, Brakenhoff JP, et al. Multi-omics 755 analysis reveals microRNAs associated with cardiometabolic traits. Frontiers in genetics. 756 2020; 11 110.
- (48) Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, et al. miR-757
- 758 133 and miR-30 regulate connective tissue growth factor: implications for a role of
- 759 microRNAs in myocardial matrix remodeling. Circulation research. 2009; 104 (2): 170-178.
- 760 (49) Backes C, Kehl T, Stöckel D, Fehlmann T, Schneider L, Meese E, et al. miRPathDB: a 761 new dictionary on microRNAs and target pathways. Nucleic acids research. 2016; gkw926.
- 762 (50) Mantilla-Escalante DC, López de las Hazas, María-Carmen, Gil-Zamorano J, del Pozo-763 Acebo L, Crespo MC, Martín-Hernández R, et al. Postprandial circulating miRNAs in 764 response to a dietary fat challenge. Nutrients. 2019; 11 (6): 1326.
- (51) Li Y, Xiao L, Li J, Sun P, Shang L, Zhang J, et al. MicroRNA profiling of diabetic 765 766 atherosclerosis in a rat model. European journal of medical research. 2018; 23 (1): 1-10.
- 767 (52) Mo Y, Fang R, Wu J, Si Y, Jia S, Li Q, et al. MicroRNA-329 upregulation impairs the 768 HMGB2/β-catenin pathway and regulates cell biological behaviors in melanoma. Journal of 769 cellular physiology. 2019; 234 (12): 23518-23527.
- 770 (53) Võsa U, Claringbould A, Westra H, Bonder MJ, Deelen P, Zeng B, et al. Large-scale 771 cis-and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that 772 regulate blood gene expression. Nature genetics. 2021; 1-11.
- 773 (54) Westra H, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. 774 Systematic identification of trans eQTLs as putative drivers of known disease associations. 775 Nature genetics. 2013; 45 (10): 1238-1243.
- 776 (55) Yao C, Joehanes R, Johnson AD, Huan T, Liu C, Freedman JE, et al. Dynamic role of 777 trans regulation of gene expression in relation to complex traits. The American Journal of 778 Human Genetics. 2017; 100 (4): 571-580.
- (56) GTEx Consortium. Genetic effects on gene expression across human tissues. Nature. 779 780 2017; 550 (7675): 204-213.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- (57) Shah R, Tanriverdi K, Levy D, Larson M, Gerstein M, Mick E, et al. Discordant 781
- 782 expression of circulating microRNA from cellular and extracellular sources. PloS one. 2016; 783 11 (4): e0153691.

784 (58) Roshchupkin GV, Adams H, Vernooij MW, Hofman A, Van Duijn CM, Ikram MA, et al. 785 HASE: Framework for efficient high-dimensional association analyses. Scientific reports. 786 2016; 6 36076.

- 787 (59) Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-788 specific haplotype structure and linking correlated alleles of possible functional variants. 789 Bioinformatics. 2015; 31 (21): 3555-3557.
- 790 (60) Gong J, Liu C, Liu W, Wu Y, Ma Z, Chen H, et al. An update of miRNASNP database 791 for better SNP selection by GWAS data, miRNA expression and online tools. Database. 792 2015; 2015.
- 793 (61) MHC Sequencing Consortium. Complete sequence and gene map of a human major 794 histocompatibility complex. Nature. 1999; 401 (6756): 921-923.
- 795 (62) Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex 796 trait analysis. The American Journal of Human Genetics. 2011; 88 (1): 76-82.
- 797 (63) Hinske LC, Franca GS, Torres HA, Ohara DT, Lopes-Ramos CM, Heyn J, et al. 798 miRIAD-integrating microRNA inter-and intragenic data. Database. 2014; 2014.
- 799 (64) Verma A, Bradford Y, Dudek S, Lucas AM, Verma SS, Pendergrass SA, et al. A 800 simulation study investigating power estimates in phenome-wide association studies. BMC 801 bioinformatics. 2018; 19 (1): 120.
- 802 (65) Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for 803 phenome-wide association studies in the R environment. *Bioinformatics*. 2014; 30 (16): 804 2375-2376.

805 (66) Burgess S, Thompson SG, CRP CHD Genetics Collaboration. Avoiding bias from weak 806 instruments in Mendelian randomization studies. International journal of epidemiology. 2011; 807 40 (3): 755-764.

- 808 (67) Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful 809 approach to multiple testing. Journal of the Royal statistical society: series B 810 (Methodological). 1995; 57 (1): 289-300.
- 811 (68) Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with 812 multiple genetic variants using summarized data. Genetic epidemiology. 2013; 37 (7): 658-813 665.
- 814 (69) Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using 815 the MR-Egger method. European journal of epidemiology. 2017; 32 (5): 377-389.
- (70) Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid 816
- 817 instruments: effect estimation and bias detection through Egger regression. International
- 818 journal of epidemiology. 2015; 44 (2): 512-525.

- 819 (71) Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian
- 820 randomization with some invalid instruments using a weighted median estimator. Genetic
- 821 epidemiology. 2016; 40 (4): 304-314.
- 822 (72) Verbanck M, Chen C, Neale B, Do R. Detection of widespread horizontal pleiotropy in
- 823 causal relationships inferred from Mendelian randomization between complex traits and
- 824 diseases. Nature genetics. 2018; 50 (5): 693-698.

825

Tables

Table 1. The results of Mendelian randomisation (MR-IVW) for replicated associations.

exposure	MR-PheWAS							Replication						
	outcome	n	beta	SE	Р	P-het	Egger int P	outcome	n	beta	SE	Р	P-het	Egger int P
Replication in	n extended-MR													
miR-30d-5p	angina pectoris	5	-0.47	0.10	1.5×10⁻ ⁶	3.4×10 ⁻¹	2.9×10 ⁻¹	angina pectoris	6	-0.34	0.12	6.0×10 ⁻³	3.1×10 ⁻²	2.7×10 ⁻¹
	coronary atherosclerosis	5	-0.39	0.09	7.6×10 ⁻⁶	3.6×10 ⁻¹	2.5×10 ⁻¹	coronary atherosclerosis	6	-0.26	0.11	1.8×10 ⁻²	2.8×10 ⁻²	2.4×10 ⁻¹
	nephrotic syndrome	5	1.91	0.41	3.9×10 ⁻⁶	6.1×10 ⁻¹	5.7×10 ⁻¹	nephrotic syndrome	6	1.32	0.50	8.9×10 ⁻³	7.0×10 ⁻²	9.9×10 ⁻¹
	nonspecific chest pain	5	-3.07	0.56	4.9×10 ⁻⁸	7.9×10 ⁻¹	9.2×10 ⁻¹	nonspecific chest pain	6	-2.03	0.82	1.4×10 ⁻²	1.2×10 ⁻²	6.5×10 ⁻¹
miR-323b-3p	melanomas of skin	6	0.45	0.08	1.4×10 ⁻⁷	8.8×10 ⁻¹	5.7×10 ⁻¹	melanomas of skin	7	0.31	0.11	4.7×10 ⁻³	4.3×10 ⁻²	8.1×10 ⁻¹
	obesity	6	-0.16	0.03	6.6×10 ⁻⁶	7.7×10 ⁻¹	7.1×10 ⁻¹	obesity	7	-0.11	0.05	1.9×10 ⁻²	4.6×10 ⁻²	8.7×10 ⁻¹
	overweight or obesity	6	-0.15	0.03	8.5×10⁻ ⁶	7.1×10 ⁻¹	6.9×10 ⁻¹	overweight or obesity	7	-0.11	0.04	1.7×10 ⁻²	5.6×10 ⁻²	8.6×10 ⁻¹
	skin cancer	6	0.26	0.05	2.2×10 ⁻⁷	2.9×10 ⁻¹	9.6×10 ⁻¹	skin cancer	7	0.21	0.06	3.4×10 ⁻⁴	5.2×10 ⁻²	9.0×10 ⁻¹
	viral enteritis	6	0.72	0.15	1.7×10⁻ ⁶	8.7×10 ⁻¹	7.3×10 ⁻¹	viral enteritis	7	0.61	0.13	3.2×10 ⁻⁶	6.7×10 ⁻¹	6.6×10 ⁻¹
miR-409-3p	melanomas of skin	12	0.25	0.05	7.7×10 ⁻⁶	1.1×10 ⁻¹	5.0×10 ⁻¹	melanomas of skin	13	0.24	0.05	3.3×10 ⁻⁶	1.4×10 ⁻¹	4.7×10 ⁻¹
Replication u	sing GWAS summary stat	istic	s											
miR-329-3p	overweight or obesity	10	-0.15	0.03	1.5×10 ⁻⁷	3.2×10 ⁻¹	2.4×10 ⁻¹	BMI	6	-0.03	0.01	1.9×10 ⁻²	4.9×10 ⁻⁷	9.9×10 ⁻²
	obesity	10	-0.15	0.03	3.9×10 ⁻⁸	3.5×10⁻¹	2.4×10 ⁻¹							
miR-543	overweight or obesity	8	-0.15	0.03	9.5×10 ⁻⁹	4.7×10⁻¹	8.4×10 ⁻¹	WHR	7	-0.02	0.01	1.7×10 ⁻²	7.7×10 ⁻¹	9.0×10 ⁻¹
	obesity	8	-0.15	0.03	1.1×10 ⁻⁸	4.9×10 ⁻¹	8.9×10 ⁻¹							

BMI: body mass index. WHR: waist-to-hip ratio. n is the number of genetic instruments used in the analysis. SE: standard error. P-het denotes P-value for heterogeneity of MR-IVW estimates. Egger int P: P-values for MR Egger intercept. The summary statistics presented are based on MR-IVW. Full results for other MR methods are presented in Supplementary Tables 25 and 26.

Figure Legends

Figure 1. Overview of the study workflow.

Figure 2. a. Fujiplot of identified and replicated miR-eQTLs mapped into 22 genomic loci. Each circular layer represents miRNA, and dots represent SNP-miRNA associations. The dots that form a radial pattern indicate loci associated with multiple miRNAs. The innermost histogram shows the number of miR-eQTLs identified in each locus. ** in chromosome 5 represents one locus mapped to *CTC-5298P.1*. The top-left inset is a barplot to show the number of independent cis and trans-miR-eQTLs in pleiotropic loci, each regulating the level of multiple miRNAs. Highly pleiotropic loci were identified in locus chr14:100655022-101244293, regulating 23 miRNAs, the majority of which were cis-miR-eQTLs. The locus in chr9:136128546-136296530 consisted of trans-miR-eQTLs and regulated 18 miRNAs. **b. Functional consequences of identified miR-eQTLs on nearby and far genes. c. SNP-based heritability estimates distribution for 2,083 miRNAs**.

Figure 3. a. Overlap between cis miR-eQTLs and proteins (pQTLs). The bottom half of the circle shows miRNAs in different colours, and the top half of the circle (grey coloured) shows the genes. b. Overlap between trans-miR-eQTLs and proteins (pQTLs). Trans-miR-eQTLs are shown to be more pleiotropic than cis-miR-eQTLs.

Figure 4. a. Summary of PheWAS and MR. Cis-miR-eQTLs were used as proxies for miRNAs. When multiple cis-miR-eQTLs were available, cis-GRS was computed for PheWAS. Otherwise, single variant PheWAS was conducted. MR were conducted for miRNA with at least three instruments. When available, large GWAS data were used to replicate the findings. Otherwise, genome-wide trans-miR-eQTLs were added in the extended-MR. b. Number of cases available within each disease group. The figure corresponds to clinical diagnoses with at least 200 cases.**c. Enhanced volcano plots for single variant PheWAS and d. GRS PheWAS.** The X-axis denotes effect estimates for corresponding SNP or GRS. Y-axis indicates -log10 of the association p-values between each SNP or GRS and clinical condition. Different colours of the dots represent different SNPs. Different shapes show different disease groups. Thresholds of significance are indicated by dashed blue (nominal), red (FDR), and purple (Bonferroni) lines. Plots were only created for SNP and GRS with at least one FDR-significant finding.

Figure 5. a. Number of miRNAs associated with diagnoses in each disease group as identified in PheWAS. b. Schematic network showing miRNAs and disease groups associations. Each line corresponds to association between miRNA and clinical diagnosis that belong to a particular disease group. The colour of the circles indicates miRNA (orange) or disease groups (green). c. Forest plots for 24 associations in MR-PheWAS with no genome-wide significant trans-miR-eQTLs. Different colours correspond to different MR methods, as labelled.























с.



Extended Data Figures



Extended Data Fig. 1. Selection of study participants in the Rotterdam Study.



Extended Data Fig. 2. Identification of miR-eQTLs and replication in independent cohorts. In total, 3,292 significant associations were discovered for 63 miRNAs. Of those 1,462 out of 2,254 associations available in Nikpay et al. (9) were replicated for 27 miRNAs (P<0.05/58). On the other hand, 2,957 associations identified by Nikpay et al. (9) for 34 miRNAs were replicated (P<0.05/52) and 1,320 associations for 29 miRNAs identified in the Framingham Heart Study (10) were also replicated (P<0.05/195). Collectively, 4,310 associations for 64 miRNAs were successfully replicated across studies.



Extended Data Fig. 3. Correlation of effect estimates between discovery and replication of miR-eQTLs. a. Associations in the Rotterdam Study that were replicated in Nikpay et al.(9). b. Associations in Nikpay et al. (9) that were replicated in the Rotterdam Study. c. Associations in the Framingham Study that were replicated in the Rotterdam Study.



Extended Data Fig. 4. Regional plot for genomic risk loci in chr 14:100655022-101244293 harbouring cis-miR-eQTLs for 31 miRNAs that are clustered together. Plot was extracted from FUMA.



Extended Data Fig. 5. Pearson correlation of heritability estimates with and without principal components.



Extended Data Fig. 6. Selection of participants for PheWAS and MR-PheWAS in the UK Biobank.



Extended Data Fig. 7. Scatter plots for MR-PheWAS and replication MR (bottom). a. miR-543 and obesity (left) and waist to hip ratio (right). b. miR-329-3p and obesity (left) and body mass index (right).